Drug Trial Radar · NCT07326566
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
162
Planned (sponsor's estimate)
Start
May 5, 2026
Primary completion
Nov 2028
Study completion Mar 2029
Sponsor
- Lead sponsor
- Black Diamond Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to see if combining silevertinib with temozolomide after surgery and radiotherapy helps treat newly diagnosed glioblastoma (GBM) better than using temozolomide alone in the maintenance setting. Specifically, this study is being done to find answers to the following questions: * How much of the study drugs (silevertinib combined with temozolomide) should be given to participants with GBM? * What are the side effects participants have when taking the study drug (silevertinib combined with temozolomide)? * Can the study drug (silevertinib combined with temozolomide) help participants with GBM live longer without disease progression compared to treatment with temozolomide alone?
Conditions
- Glioblastoma (GBM)
- Newly Diagnosed Glioblastoma
- GBM
- Glioblastoma Multiforme (GBM)
- Glioma
- Central Nervous System Diseases
- Brain Cancer
Interventions
silevertinib in combination with temozolomideDrug
Participants enrolled into Part 1 (Safety Lead-In) or randomized to Arm A in Part 2 will receive silevertinib at dose determined in Part 1 until disease progression in combination with temozolomide 150-200 mg/m2 orally once daily on Days 1 to 5 of each 28-day cycle for maximum of 6 cycles.
temozolomide (TMZ)Drug
Participants randomized to Arm B will receive temozolomide 150-200 mg/m2 orally once daily on Days 1 to 5 of each 28-day cycle for maximum of 6 cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR)Time frame: 12 months
Locations
39 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham O'Neal Comprehensive Cancer Center
Birmingham, Alabama · Recruiting
Highlands Oncology Group
Springdale, Arkansas · Recruiting
UCSD Moores Cancer Center
La Jolla, California · Recruiting
Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
UC Irvine Health
Orange, California · Recruiting
Stanford University
Palo Alto, California · Recruiting
Yale Cancer Center
New Haven, Connecticut · Recruiting
Johns Hopkins Sibley Memorial Hospital
Washington D.C., District of Columbia · Recruiting
Miami Cancer Institute
Miami, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Piedmont Oncology Research
Atlanta, Georgia · Recruiting
Maine Health Cancer Care and Blood Disorders - Scarborough
Scarborough, Maine · Recruiting
Johns Hopkins Sidney Kimmel Cancer Center - Baltimore
Baltimore, Maryland · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Henry Ford Cancer- Detroit
Detroit, Michigan · Recruiting
Atrium Health Levine Cancer Institute
Minneapolis, Minnesota · Recruiting
Washington University School of Medicine Siteman Cancer Center
St Louis, Missouri · Recruiting
University of Nebraska Medical Center
Omaha, Nebraska · Recruiting
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey · Recruiting
Rutgers Cancer Institute
New Brunswick, New Jersey · Recruiting
Atlantic Health
Summit, New Jersey · Recruiting
Northwell Health Center for Advanced Medicine - Brain Tumor Center
Lake Success, New York · Recruiting
Columbia University Irving Medical Center
New York, New York · Recruiting
Montefiore Medical Center
The Bronx, New York · Recruiting
Atrium Health Levine Cancer Institute
Charlotte, North Carolina · Recruiting
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina · Recruiting
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio · Recruiting
Ohio State University
Columbus, Ohio · Recruiting
Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center
Philadelphia, Pennsylvania · Recruiting
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
Prisma Health
Greenville, South Carolina · Recruiting
UT MD Anderson Cancer Center
Houston, Texas · Recruiting
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah · Recruiting
Inova Schar Cancer Institute
Fairfax, Virginia · Recruiting
VCU Massey Comprehensive Cancer Center
Richmond, Virginia · Recruiting
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.